1. Introduction {#sec1-jcm-09-01251}
===============

Chronic Venous Disease (CVD) is a common vascular disease of the lower limbs. Estimates of the worldwide prevalence of symptomatic CVD range as high as 60% \[[@B1-jcm-09-01251],[@B2-jcm-09-01251]\]. The common risk factors include age, obesity, smoking, low physical activity, periods of prolonged standing or sitting and positive family history \[[@B2-jcm-09-01251]\]. CVD is defined as a syndrome of chronic morphological and functional abnormalities of the venous system, manifested either by symptoms (including tingling, aching, burning, pain, muscle cramps, swelling, sensations of throbbing or heaviness, itching, restless legs, leg tiredness and fatigue) or clinical signs prompting the need for investigation and medical care \[[@B3-jcm-09-01251]\]. The disease encompasses a wide spectrum of clinical presentations such as telangiectasia, varicose veins, leg edema, skin changes and ulcers, as included in the Clinical, Etiology, Anatomic, Pathophysiology (CEAP) classification \[[@B4-jcm-09-01251],[@B5-jcm-09-01251],[@B6-jcm-09-01251]\]. Chronic Venous Insufficiency (CVI) is a term reserved for advanced CVD, which is applied to functional abnormalities of the venous system producing edema, skin changes, or venous ulcers (C3--C6 in CEAP classification) \[[@B3-jcm-09-01251]\].

CVD is caused by hemodynamic disturbances in veins of lower limbs, presenting as venous occlusion, venous valve incompetency and calf muscle pump dysfunction, which lead to venous hypertension and reflux \[[@B5-jcm-09-01251],[@B7-jcm-09-01251],[@B8-jcm-09-01251],[@B9-jcm-09-01251]\]. In the majority of cases, the great and small saphenous veins are involved \[[@B8-jcm-09-01251]\]. The skin manifestations, such as edema, dermatitis, lipodermatosclerosis and ulceration, are the consequence of chronic volume overload and hypertension in subcutaneous veins, as well as inflammatory processes within skin tissues \[[@B10-jcm-09-01251],[@B11-jcm-09-01251]\]. Imbalance between metalloproteinases and their inhibitors as well as accumulation of leukocytes in the tissues surrounding the venous vessels of the lower limbs under high pressure conditions is considered to be the basis for chronic inflammation and pathological changes in the skin tissue of patients with chronic venous insufficiency \[[@B7-jcm-09-01251],[@B12-jcm-09-01251],[@B13-jcm-09-01251]\].

A significant decrease in life quality, caused by pain, reduced mobility and leg ulcerations, affects patients with CVD \[[@B14-jcm-09-01251],[@B15-jcm-09-01251]\].

The most recommended diagnostic procedures of CVD include physical examination and duplex ultrasound scanning, and the most effective treatment options are compression therapy and invasive interventions, complemented by pharmacotherapy \[[@B16-jcm-09-01251],[@B17-jcm-09-01251]\]. New, more effective diagnostic and treatment strategies are needed and more profound understanding of pathology, particularly the interactions between molecular and cellular mechanisms, is essential for development of optimal treatment approaches.

MicroRNA (miRNA) has been the subject of many studies, greatly expanding the knowledge of their diversity and functions \[[@B18-jcm-09-01251]\]. MiRNAs are approximately 18--25-nucleotides long, single-stranded RNAs involved in modulating gene expression pathways \[[@B19-jcm-09-01251]\]. MiRNAs incorporated in protein complex exhibit gene expression regulating effect by binding to mRNA. The pairing effect of miRNA--mRNA interactions reduces gene expression predominantly by repression of translation, destabilization and cleavage of mRNA \[[@B20-jcm-09-01251]\]. MiRNAs exert their effect as a switch and a fine-tuner of gene expression, providing a pleiotropic effect on protein pool in cells \[[@B21-jcm-09-01251]\]. Alterations in genes involved in miRNA processing were found in various human cancers \[[@B22-jcm-09-01251]\]. MiRNAs are intensively studied as potential means of novel diagnostic and treatment approaches \[[@B23-jcm-09-01251],[@B24-jcm-09-01251]\]

A growing amount of evidence suggests a relevant role of miRNA in vascular cell functions, including cell differentiation, proliferation, migration, and apoptosis \[[@B25-jcm-09-01251],[@B26-jcm-09-01251]\]. MiRNAs are involved in vascular diseases, exhibiting modulatory function of angiogenesis, endothelial cells dysfunction and response for ischemic events \[[@B27-jcm-09-01251]\]. Numerous miRNAs are considered as potential markers of cardiovascular diseases (e.g., coronary artery disease, myocardial infarction, atherosclerosis, venous thromboembolism), exhibiting promising diagnostic, prognostic and therapeutic value \[[@B27-jcm-09-01251],[@B28-jcm-09-01251],[@B29-jcm-09-01251],[@B30-jcm-09-01251],[@B31-jcm-09-01251]\].

Altered expression patterns of miRNAs and genes were demonstrated in vein specimens derived from patients with CVI and compared to healthy subjects \[[@B32-jcm-09-01251],[@B33-jcm-09-01251]\]. Dysregulation of miRNA expression, reported in venous ulcers biopsies, has been associated with inhibition of wound healing \[[@B34-jcm-09-01251]\]. The proposed role of miRNA in CVI susceptibility has also been reported \[[@B35-jcm-09-01251]\]. Therefore, miRNAs could also be involved in the pathogenesis of CVD and may be relevant as potential diagnostic and therapeutic targets.

In our work, integrated miRNA and gene expression analysis was applied to find potential robust biomarkers of CVD and to show the impact of miRNA-regulated genes on pathological processes governing CVD development.

2. Experimental Section {#sec2-jcm-09-01251}
=======================

2.1. Study Participants Characteristics {#sec2dot1-jcm-09-01251}
---------------------------------------

The study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee at Medical University of Lublin (approval No. KE-0254/341/2015). Participants were recruited between February 2016 and May 2017. All subjects gave their informed consent for inclusion before they participated in the study. The CVD group consisted of 34 patients diagnosed and hospitalized only due to CVD, without any other diagnosed vascular diseases or comorbidities, in the Independent Public Clinical Hospital No. 1 in Lublin, Poland. The control group comprised of 19 healthy volunteers without any visible CVD characteristics and lack of comorbidities during examination. Detailed characteristics of included participants are presented in [Table 1](#jcm-09-01251-t001){ref-type="table"}.

Inclusion and exclusion criteria were evaluated by a vascular surgeon. Included CVD patients were examined using tourniquet test, auscultation and duplex ultrasound scanning. Venous reflux lasting longer than 1 s was classified as pathological. Patients diagnosed with symptoms classified according to CEAP as varicose veins (C2) of superficial veins (As) with primary etiology (Ep) and reflux pathophysiology (Pr) were included. The exclusion criteria were previous vascular surgery of lower limbs, insufficiency of deep veins, acute and chronic inflammation of veins, lower extremities arterial disease, coronary artery disease, cerebrovascular disease, aneurismal disease, myocardial infarction, hypertension, stroke, diabetes mellitus type 2, and pregnancy.

Body Mass Index (BMI), pain symptoms, ankle-brachial index, smoking habits and applied medical treatment were also evaluated ([Table 1](#jcm-09-01251-t001){ref-type="table"}).

The control group consisted of 19 healthy, nonsmoking volunteers ([Table 1](#jcm-09-01251-t001){ref-type="table"}). Only subjects without blood flow disturbances and with normal morphology of veins in lower limbs, confirmed by physical examination and duplex ultrasound scanning, were included to the study as controls. Any symptoms, comorbidities and treatment of vascular diseases were indicated in the analysis of medical history of control subjects.

2.2. Study Material Preparation {#sec2dot2-jcm-09-01251}
-------------------------------

Isolation of Peripheral Blood Mononuclear Cells (PBMCs) was performed from whole blood samples by density gradient centrifugation using Gradisol L reagent (Aqua-Med, Łódź, Poland). Small RNA fractions were isolated from PBMCs samples of 34 CVD patients and 19 controls using MirVana microRNA Isolation Kit (Ambion, Austin, TX, USA), according to the manufacturer's protocol. Total RNA was isolated from PBMCs of seven randomly selected CVD patients and seven randomly selected control subjects, using TRI Reagent Solution (Applied Biosystems, Foster, CA, USA) according to the manufacturer's protocol. For a more detailed description of study material isolation and assessment refer to \[[@B30-jcm-09-01251]\].

2.3. Libraries Preparation and Sequencing {#sec2dot3-jcm-09-01251}
-----------------------------------------

Small RNA libraries were prepared from 53 small RNA samples isolated from PBMCs of 34 CVD patients and 19 healthy controls. Technical limitations did not allow to perform transcriptome sequencing for all subjects included in the study, therefore transcriptome libraries were constructed from 14 total RNA samples isolated from randomly selected, representative subsets of PBMCs samples (seven from CVD patients and seven from healthy controls).

Small RNA and transcriptome libraries were prepared using Ion Total RNA-Seq Kit v2, Magnetic Bead Cleanup Module kit and barcoded with Ion Xpress RNA-Seq Barcode 01-16 Kit (all Life Technologies, Carlsbad, CA, USA), according to the manufacturer's protocol "Ion Total RNA-Seq Kit v2" revision B.0. Libraries were sequenced on Ion 540 Chips (Life Technologies) using Ion S5 XL System (ThermoFisher Scientific, Waltham, MA, USA). Small RNA and transcriptome raw sequencing data were aligned to 2792 human miRNAs from miRBase v21 (<http://www.mirbase.org>) and to 55,765 genes and splicing variants of hg19 human genome, respectively.

Detailed description of libraries preparation and sequencing procedures were included in our previous study \[[@B30-jcm-09-01251]\].

2.4. Statistical Analysis {#sec2dot4-jcm-09-01251}
-------------------------

The differences between CVD and control groups were evaluated in terms of age and BMI using a two-sided Mann--Whitney *U* test (wilcox.test function in R), and in terms of sex and smoking using Fisher exact test (fisher.test function in R).

Statistical analysis of miRNA and gene expression datasets was performed on biological replicates using R environment (version 3.5.2, <https://www.r-project.org>) with proper packages. Differential expression analysis was carried out using DESeq2 package v1.18.1 (<https://bioconductor.org/packages/release/bioc/html/DESeq2.html>) \[[@B36-jcm-09-01251]\]. MiRNAs and genes with *p* value below 0.05 after Benjamini--Hochberg false discovery rate correction were considered as statistically significant. Differential potential of miRNAs and genes was further confirmed by Uninformative Variable Elimination by Partial Least Squares (UVE-PLS) method \[[@B37-jcm-09-01251]\] using the plsVarSel package v0.9.3 (<https://cran.r-project.org/web/packages/plsVarSel/index.html>) \[[@B38-jcm-09-01251]\].

Venn diagrams, Heatmaps with Euclidean clustering and 3D Principal Component Analysis (PCA) plots were created using VennDiagram 1.6.20 (<https://cran.r-project.org/web/packages/VennDiagram/index.html>) \[[@B39-jcm-09-01251]\], pheatmap 1.0.10 (<https://cran.r-project.org/web/packages/pheatmap/index.html>) and scatterplot3d 0.3-41 (<https://cran.r-project.org/web/packages/scatterplot3d/index.html>) \[[@B40-jcm-09-01251]\] packages, respectively. Correlation analysis was performed using Spearman rank correlation test implemented in the Hmisc package 4.4-0 (<https://cran.r-project.org/web/packages/Hmisc/index.html>).

A Receiver Operating Characteristics (ROC) analysis implemented in pROC package 1.12.1 \[[@B41-jcm-09-01251]\] (<https://cran.r-project.org/web/packages/pROC/index.html>) was used to evaluate the predictive value of selected miRNAs and gene transcripts for CVD classification.

Deconvolution of gene expression was performed by "quanTIseq" \[[@B42-jcm-09-01251]\] and "MCPcounter" \[[@B43-jcm-09-01251]\] methods implemented to immunedeconv 2.0.0 package (<https://rdrr.io/github/grst/immunedeconv/>) \[[@B44-jcm-09-01251]\].

MultiMiR package 1.2.0 (<https://bioconductor.org/packages/release/bioc/html/multiMiR.html>) \[[@B45-jcm-09-01251]\] was used to identify validated and predicted interactions between selected miRNAs and genes. Visualization of the regulatory network with interactions was performed using Cytoscape v3.5.1 software (<https://cytoscape.org/>) \[[@B46-jcm-09-01251]\].

Functional analysis of networked genes was performed using Database for Annotation, Visualization and Integrated Discovery (DAVID) 6.8 tool (<https://david.ncifcrf.gov/>) \[[@B47-jcm-09-01251],[@B48-jcm-09-01251]\]. Default whole genome of *Homo sapiens* was applied as a background. All the terms of Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome and Genetic Association Database (GAD) databases associated with analyzed genes were harvested. Enrichment analysis of functional terms was proceeded for Gene Ontology (GO) terms separately for up- and downregulated genes.

All statistical procedures applied to this study were previously described in detail in \[[@B30-jcm-09-01251]\]. Statistical analysis and visualizations were performed according to R code available in published reference manuals of used packages.

The summarized methodology applied in our study is presented on [Figure 1](#jcm-09-01251-f001){ref-type="fig"}.

3. Results {#sec3-jcm-09-01251}
==========

3.1. Study Population Analysis {#sec3dot1-jcm-09-01251}
------------------------------

Characteristics of 34 patients with CVD and 19 non-CVD controls are presented in [Table 1](#jcm-09-01251-t001){ref-type="table"}. A statistically significant difference between these groups was observed in age (*p* = 8.387 × 10^−3^) and smoking history (*p* = 1.296 × 10^−4^), which probably results from inclusion of healthy CVD-negative non-smoking individuals in control group. No statistically significant differences between CVD and control groups concerning gender and BMI were found ([Table 1](#jcm-09-01251-t001){ref-type="table"}, [Figure S1](#app1-jcm-09-01251){ref-type="app"}).

3.2. Primary Results {#sec3dot2-jcm-09-01251}
--------------------

Detailed description of small RNA samples and small RNA libraries as well as the results of primary analysis of small RNA libraries sequencing data are presented in [Table S1](#app1-jcm-09-01251){ref-type="app"}. Detailed description of transcriptome libraries and results of primary analysis of transcriptome libraries sequencing data are presented in [Table S2](#app1-jcm-09-01251){ref-type="app"}. Plots depicting sequencing data quality, including boxplot of Cook's distances, MA plot and histogram of *p* values, regarding small RNA and transcriptome sequencing are presented in [Figure S2 and Figure S3](#app1-jcm-09-01251){ref-type="app"}, respectively.

3.3. Differential Expression Analysis of miRNA {#sec3dot3-jcm-09-01251}
----------------------------------------------

The comparison of miRNA expression levels between 34 CVD patients and 19 non-CVD controls was performed using DESeq2 and UVE-PLS methods and significantly dysregulated miRNAs selected by both methods were chosen.

DESeq2 analysis revealed 1034 differentially expressed miRNA transcripts in CVD subjects compared to controls. Ninety-six miRNA transcripts were differentially expressed with statistical significance *p* \< 0.05 ([Table S3](#app1-jcm-09-01251){ref-type="app"}). DESeq2 method is characterized by relatively high sensitivity, therefore a set of 49 differentially expressed miRNA transcripts (for 41 miRNAs) of higher significance (*p* \< 0.01) was selected to limit the number of potentially false positive results.

In order to optimally filter uninformative miRNAs, the UVE-PLS method was applied to miRNA expression data of 1034 differentially expressed miRNA transcripts in CVD subjects. UVE-PLS analysis returned 48 informative miRNA transcripts ([Table S4](#app1-jcm-09-01251){ref-type="app"}). [Figure S4](#app1-jcm-09-01251){ref-type="app"} shows the arrangement of prediction error and PLS components as well as cross-validated predictions versus measured values.

The set of 49 differentially expressed miRNA transcripts identified by DESeq2 method (with *p* \< 0.01) and the set of 48 differentially expressed miRNA transcripts identified by UVE-PLS method were compared on the Venn diagram, revealing 34 miRNA transcripts common for both sets ([Figure 2](#jcm-09-01251-f002){ref-type="fig"}a). These 34 miRNA transcripts result in 31 miRNAs (22 upregulated and 9 downregulated), which constitute a proposed panel of potential miRNA biomarkers of CVD ([Table 2](#jcm-09-01251-t002){ref-type="table"}). Differential expression of common 34 miRNA transcripts in CVD and control group is visualized on 3D PCA plot and in heatmap with Euclidean clustering ([Figure 2](#jcm-09-01251-f002){ref-type="fig"}b,c, respectively).

ROC analysis revealed that areas under ROC curves for 34 selected miRNA transcripts were covered in the range 0.930--0.757, indicating a high ability to distinguish patients with CVD from healthy subjects ([Table 2](#jcm-09-01251-t002){ref-type="table"}, [Table S5 and Figure S5](#app1-jcm-09-01251){ref-type="app"}).

Correlation analysis between age and expression data of 34 selected miRNA transcripts was performed in CVD group in order to evaluate effect of age on these miRNAs ([Table S6](#app1-jcm-09-01251){ref-type="app"}). Only hsa-miR-548ac was statistically significantly correlated with age (*p* = 0.0395) exhibiting weak and negative correlation (R = −0.35). The lack of statistically significant correlation of remaining 33 miRNA transcripts suggests their independency from age; however, further studies with larger populations should be performed to confirm this result.

3.4. Differential Expression Analysis of Genes {#sec3dot4-jcm-09-01251}
----------------------------------------------

From CVD patient and non-CVD control groups, seven patients and seven controls were randomly selected for gene expression analysis. Similarly to miRNA, DESeq2 and UVE-PLS methods were applied to perform differential gene expression analysis. Significantly dysregulated genes revealed by both methods were selected.

DESeq2 analysis disclosed 23,204 differentially expressed genes in CVD subjects, comparing to controls. In total, 2719 genes presented statistical significance (*p* \< 0.05). The risk of false positive results was decreased by selection of 183 differentially expressed genes with *p* \< 0.00001 ([Table S7](#app1-jcm-09-01251){ref-type="app"}).

Application of UVE-PLS analysis to gene expression data of 23,204 differentially expressed genes in CVD subjects compared to controls disclosed 74 informative genes ([Table S8](#app1-jcm-09-01251){ref-type="app"}). Plot presenting the arrangement of prediction error and PLS components as well as plot of cross-validated predictions versus measured values were shown on [Figure S6](#app1-jcm-09-01251){ref-type="app"}.

The set of 183 differentially expressed genes identified by DESeq2 method with *p* \< 0.00001 and the set of 74 informative genes identified by UVE-PLS method were compared on a Venn diagram, revealing 62 genes common for both sets ([Figure 3](#jcm-09-01251-f003){ref-type="fig"}a). These 62 common genes constitute a proposed panel of potential biomarkers of CVD ([Table 3](#jcm-09-01251-t003){ref-type="table"}). Clustering patterns of 62 genes in CVD subjects and controls was visualized on 3D PCA plot and in heatmap with Euclidean clustering ([Figure 3](#jcm-09-01251-f003){ref-type="fig"}b,c, respectively).

The ROC analysis showed that areas under ROC curves obtained for 62 selected genes were equal to 0.98 for *RAC1P2* and *RP11-318C24.1*, and equal to one for the remaining 60 genes, indicating good precision of CVD classification ([Table 3](#jcm-09-01251-t003){ref-type="table"}, [Table S9, Figure S7](#app1-jcm-09-01251){ref-type="app"}).

Correlation analysis between age and expression data of 62 selected genes was performed in CVD group in order to evaluate effect of age on these genes ([Table S10](#app1-jcm-09-01251){ref-type="app"}). *HSPA8P1* (R = −0.82, *p* = 0.024), *PTBP1P* (R = −0.80, *p* = 0.031), *TSC2* (R = −0.79, *p* = 0.033) and *UBA52P5* (R = −0.77, *p* = 0.043) were statistically significantly and negatively correlated with age. Among these four genes, *HSPA8P1*, *PTBP1P* and *UBA52P5* were disclosed as downregulated in CVD group, pointing to them as possible age-associated risk factors of CVD. A lack of statistically significant correlation of remaining 58 genes suggests their independency from age; however, further studies with larger populations should be performed to confirm this result.

To estimate the influence of cell subpopulations diversity in the PBMCs samples on results of gene expression analysis, the deconvolution procedure was carried out using "quanTIseq" and "MCPcounter" methods implemented in immunedeconv package. Both methods enable to perform comparisons between samples and "quanTIseq" allows also to make comparisons between cell types. Application of both methods to the gene expression data showed estimated proportions of 11 cell subpopulations in studied samples ([Figures S8 and S9](#app1-jcm-09-01251){ref-type="app"}). Although differences in proportions of particular cell subpopulations could be observed between samples, our data suggests that there is no significant impact of cell subpopulations composition in PBMCs samples on the study results.

3.5. In Silico Identification of miRNA:Gene Interactions {#sec3dot5-jcm-09-01251}
--------------------------------------------------------

Identification of miRNA:gene interactions between 31 selected miRNAs and 62 selected genes was performed in silico by multiMiR package. Twelve validated ([Table S11](#app1-jcm-09-01251){ref-type="app"}) and 51 top 10%-predicted miRNA:gene pairs ([Table S12](#app1-jcm-09-01251){ref-type="app"}) were returned from analysis. Interactions between miRNAs and their targets were visualized as a regulatory network containing 22 miRNAs and seven genes ([Figure 4](#jcm-09-01251-f004){ref-type="fig"}).

3.6. Functional Analysis of miRNA Targets {#sec3dot6-jcm-09-01251}
-----------------------------------------

Functional analysis was performed using DAVID 6.8 tool for seven networked target genes (*CDS2*, *HDAC5*, *PPP6R2*, *PRRC2B*, *TBC1D22A*, *WNK1*, and *PABPC3*). Analyzed genes were associated with cardiovascular diseases and risk factors (*TBC1D22A*, *WNK1*), bone mineral density (*HDAC5*), body weight (*PABPC3*), glycerophospholipid metabolism (*CDS2*), Notch signaling (*HDAC5*), RNA transport and degradation (*PABPC3*). Three genes: *CDS2*, *TBC1D22A*, and *WNK1* were connected to tobacco use disorder, which may be caused by the prevalence of smoking in 14.7% of CVD population (control group consists of non-smoking individuals, [Table 1](#jcm-09-01251-t001){ref-type="table"}). GO enrichment analysis assigned upregulated genes (*CDS2*, *HDAC5*, *PPP6R2*, *PRRC2B*, *TBC1D22A*, and *WNK1*) to developmental processes and downregulated gene *PABPC3* to RNA metabolic processes ([Table 4](#jcm-09-01251-t004){ref-type="table"}).

4. Discussion {#sec4-jcm-09-01251}
=============

High prevalence, multifactorial character and diverse symptomatology of CVD make this disease one of the major health problems worldwide \[[@B49-jcm-09-01251]\]. There is a lack of sensitive and specific biomarkers for early detection of CVD and for monitoring disease progression. Altered expression of miRNA and its effects on regulation of gene expression make it a promising candidate for novel diagnostic and treatment approaches.

In the presented study, we conducted integrated, comparative analysis of miRNA and gene expression in PBMCs of patients with CVD and healthy controls. We applied Next Generation Sequencing and various statistical and bioinformatic tools to analyze expression profiles of CVD patients vs. controls and to search for genetic signatures of CVD ([Figure 1](#jcm-09-01251-f001){ref-type="fig"}). Most promisingly, 31 miRNAs ([Table 2](#jcm-09-01251-t002){ref-type="table"}) and 62 genes ([Table 3](#jcm-09-01251-t003){ref-type="table"}), which potentially may serve as biomarkers for CVD, were selected. The discriminative character of proposed biomarkers was reinforced by decreasing the *p* value of statistical significance in DESeq2 analysis (*p* \< 0.01 for miRNAs and *p* \< 0.00001 for genes, refer to [Table 2](#jcm-09-01251-t002){ref-type="table"} and [Table 3](#jcm-09-01251-t003){ref-type="table"}, respectively) and elimination of uninformative variables using the UVE-PLS method. In ROC analysis, we confirmed very solid diagnostic value of proposed biomarkers ([Table 2](#jcm-09-01251-t002){ref-type="table"} and [Table 3](#jcm-09-01251-t003){ref-type="table"}, [Tables S5 and S9, Figures S5 and S7](#app1-jcm-09-01251){ref-type="app"}). This multi-step procedure with strict criteria was applied to obtain scientifically valid results and to eliminate RT-qPCR validation.

The presented miRNA and gene signatures of CVD expand the diagnostic perspective; however, the study population is relatively minor, especially in case of transcriptomic analysis and evaluation with larger cohorts is required to confirm diagnostic utility and discriminative ability of proposed CVD biomarkers.

Integration of miRNA and gene expression analysis in this study allowed us to determine the framework of miRNA regulatory network in CVD, introducing experimentally validated and predictive interactions between significantly differentially expressed miRNA and genes found in patients with CVD ([Figure 4](#jcm-09-01251-f004){ref-type="fig"}). The findings of this study expand our understanding of miRNA functions and provide more insights into a complex network of post-transcriptional control in CVD.

To date, the topic of miRNA and gene expression analysis in venous disorders has not been sufficiently studied \[[@B33-jcm-09-01251],[@B34-jcm-09-01251]\]. Cui et al. used microarray and RT-PCR to research upregulation of miR-34a, miR-202 and downregulation of miR-155 in vein biopsies from patients with CVI \[[@B33-jcm-09-01251]\]. Our study confirmed that upregulated expression of miR-34a is indicative for chronic venous disorder.

Significantly higher expression of miR-16, miR-20a, miR-21, miR-106a, miR-203 and miR-130a was reported in skin biopsies from venous ulcers, comparing to normal skin specimens. Overexpression of these miRNAs was associated with inhibition of wound healing through targeting mRNA for EGR3, Vcl and LepR. Administration of miR-21 mimics in rat acute wound healing models leads to increase in infiltration of immune cells and reduction of epithelialization \[[@B34-jcm-09-01251]\]. In our study, we demonstrated statistically significant upregulation of miR-21 ([Table S3](#app1-jcm-09-01251){ref-type="app"}) in CVD subjects with varicose veins, which can be classified as an early stage of the disease. Therefore, enhanced signaling of miR-21 appears to be a factor involved in CVD progression both in early and advanced stages of disease development.

In other studies, miR-34a and miR-21 were significantly upregulated in plasma and in atherosclerotic plaques of patients with CAD (Coronary Artery Disease) \[[@B50-jcm-09-01251],[@B51-jcm-09-01251]\], suggesting that overexpression of miR-34a and miR-21 also found in our study to is common for both arterial and venous pathology. Diagnostic and prognostic potential of increased level of miR-21 was also reported as oncomiR in many types of cancer, including Hodgkin lymphoma \[[@B52-jcm-09-01251]\], head and neck squamous cell carcinoma \[[@B53-jcm-09-01251]\] and lung cancer \[[@B54-jcm-09-01251],[@B55-jcm-09-01251]\], while miR-34a acts as tumor suppressor and undergo epigenetic silencing in carcinogenesis \[[@B56-jcm-09-01251]\].

Some studies indicated altered expression of genes in veins obtained from patients with CVD and venous ulcers \[[@B57-jcm-09-01251],[@B58-jcm-09-01251],[@B59-jcm-09-01251],[@B60-jcm-09-01251]\] but none of the genes indicated in abovementioned research were found in our study. These differences could be related to the biological material type, inclusion criteria and methodological approach.

Presented miRNA regulatory network shows that upregulation of *WNK1* is associated with downregulation of miR-181a-2-3p and miR-106b-3p ([Figure 4](#jcm-09-01251-f004){ref-type="fig"}). *WNK1* is important for proper proliferation, chemotaxis and invasion of endothelial cells \[[@B61-jcm-09-01251]\]. Deficiency of the *WNK1* gene in mice induces embryonic lethality due to angiogenic and cardiovascular defects \[[@B61-jcm-09-01251]\]. MiRNAs belonging to miR-181 family play a key role in vascular inflammation through regulation of NF-κB signaling, activation of endothelial cells and homeostasis of immune cells \[[@B62-jcm-09-01251]\]. Upregulation of miR-181a in THP-1 cells exposed to oxidated LDL, lipopolysaccharides and phorbol myristate leads to reduction of foam cells formation and inflammatory cytokines levels, lower production of reactive oxygen species and inhibition of apoptosis \[[@B63-jcm-09-01251],[@B64-jcm-09-01251]\]. A higher level of miR-181a in plasma was proposed as a biomarker of myocardial infarction \[[@B65-jcm-09-01251]\]. Overexpression of miR-106b-3p was previously described in the late stage of endothelial replicative senescence \[[@B66-jcm-09-01251]\]. Downregulation of miR-106b-3p was observed in human retinal pigment epithelium cells (ARPE-19) exposed to hydrogen peroxide (H~2~O~2~) \[[@B67-jcm-09-01251]\]. Therefore, we hypothesize that upregulation of *WNK1* observed in our study, associated with downregulation of miR-181a-2-3p and miR-106b-3p is a possible mechanism promoting inflammation and aging in response to oxidative stress in CVD.

*WNK1* was identified in our study as a putative target for downregulated miR-128-3p ([Figure 4](#jcm-09-01251-f004){ref-type="fig"}). Zhou et al. showed that downregulation of miR-128-3p promotes endothelial cell proliferation through Ca^2+^ and ERK1/2-Akt signaling \[[@B68-jcm-09-01251]\]. Upregulation of *WNK1* as a consequence of miR-128-3p downregulation may constitute the mechanism promoting endothelial cell proliferation in CVD. Downregulation of miR-128-3p could also be a factor alleviating inflammation, since it was reported to stimulate inflammation via targeting the *TNFAIP3* gene and enhancing NF-κB signaling \[[@B69-jcm-09-01251]\].

MiRNA regulatory network of CVD ([Figure 4](#jcm-09-01251-f004){ref-type="fig"}) shows that miR-33a-5p targets *PABPC3*, which is a gene encoding a putative regulator of MEG3 stability \[[@B70-jcm-09-01251]\]. MEG3 is a suppressor of tumor growth, inhibiting proliferation and promoting apoptosis in cancer cells \[[@B71-jcm-09-01251]\] via activation of p53 \[[@B72-jcm-09-01251]\]. Our study points to downregulation of *PABPC3* with accompanying overexpression of miR-33a-5p as a factor which may affect MEG3 stability and in consequence promote cell proliferation in CVD.

Another upregulated miRNA found in CVD subjects, associated with MEG3 is miR-183-5p. This miRNA was reported to alleviate symptoms of hypoxia (such as a decrease in cell viability and migration) in H9c2 rat cardiomyocytes via targeting genes encoding MEG3 and p27 \[[@B73-jcm-09-01251]\]. Thus, the upregulation of miR-183-5p observed in our study may be considered as another factor enhancing cell proliferation and hypertrophy in CVD. Additionally, in the presented miRNA regulatory network, upregulated miR-183-5p interacts with the upregulated *WNK1* gene. This relationship may also lead to a hyper-proliferative effect, since *WNK1* has been reported to be required for proliferation of endothelial cells and vascular smooth muscle cells \[[@B61-jcm-09-01251],[@B74-jcm-09-01251]\].

In our study, downregulation of miR-769-5p in CVD patients was observed. Lower expression of this miRNA was reported in cancer cells and was associated with enhanced proliferation and reduced apoptosis \[[@B75-jcm-09-01251],[@B76-jcm-09-01251]\]. Downregulation of miR-769-5p was also found in arterial samples of abdominal and popliteal arterial aneurysm \[[@B77-jcm-09-01251]\]. In the miRNA regulatory network presented here, *HDAC5* is proposed as a putative target of miR-769-5p. Xu et al. reported that *HDAC5* mediates angiotensin II-induced MEF2 activation and vascular smooth muscle cells hypertrophy \[[@B78-jcm-09-01251]\]. These findings suggest that *HDAC5* upregulation, most likely resulted from downregulation of miR-769-5p, may be responsible for pathological vascular hypertrophy in CVD.

We indicated upregulation of miR-206 in CVD patients as an important target, which was already revealed to impair viability and migration of endothelial progenitor cells and to promote apoptosis through targeting *VEGF* \[[@B79-jcm-09-01251]\]. MiR-206 mediate silencing of *VEGF* leading to inhibition of angiogenesis during *Danio rerio* development \[[@B80-jcm-09-01251]\]. Upregulation of miR-206 in our study may thus point to inhibition of angiogenesis; however, two genes encoding downstream effectors of *VEGF* signaling, *WNK1* \[[@B81-jcm-09-01251]\] and *CDS2* \[[@B82-jcm-09-01251]\], were upregulated in CVD subjects. Upregulation of *WNK1* and *CDS2* may be a consequence of increase in *VEGF* expression mediated by chromatin remodeling caused by upregulation of *HDAC5* \[[@B83-jcm-09-01251],[@B84-jcm-09-01251]\], which was also observed in the current study. These findings may suggest an increase in angiogenesis in CVD independently from the *VEGFR* signaling. On the other hand, a different study indicated *HDAC5* as a negative regulator of angiogenesis acting through genes for pro-angiogenic factors FGF2 and Slit2 \[[@B85-jcm-09-01251]\], showing that reciprocal interaction network in CVD is more complex and requires further studies to answer all questions.

Downregulation of miR-30e-3p was previously observed in coronary microembolization and was associated with myocardial injury mediated by impairment of autophagy in cardiomyocytes \[[@B86-jcm-09-01251]\]. Therefore, the downregulation of miR-30e-3p found in this study may be involved in vascular dysfunction related to the thrombosis in CVD.

Kim and collaborators reported at least 5-fold higher level of miR-33a in plasma from individuals with high risk of atherosclerosis, compared to non-high-risk subjects \[[@B87-jcm-09-01251]\]. A significantly higher level of this miRNA was also described in PBMCs isolates from patients with CAD and was positively correlated with higher lipid levels and risk of atherosclerosis \[[@B88-jcm-09-01251],[@B89-jcm-09-01251]\]. Therefore, the upregulation of miR-33a-5p found in our study may indicate higher risk of atherosclerosis in subjects with CVD, compared to non-CVD subjects.

Upregulation of circulating miR-92a-3p was observed in the plasma of both mild cognitive impairment and Alzheimer disease subjects \[[@B90-jcm-09-01251]\] and was proposed as a biomarker of schizophrenia \[[@B91-jcm-09-01251]\]. In our study, downregulated miR-92a-3p putatively targets upregulated *PRRC2B* ([Figure 4](#jcm-09-01251-f004){ref-type="fig"}), which is a gene encoding protein involved in brain development \[[@B92-jcm-09-01251]\]. It suggests that some elements of neurodevelopmental process may also participate in CVD pathology, showing connections between vascular and neurodegenerative disorders.

The preliminary functional analysis of proposed transcriptomic biomarkers provides useful information on the pathogenesis of CVD. Functional analysis showed the association of three genes (*CDS2*, *TBC1D22A* and *WNK1*) with tobacco use disorder. The discriminative character of these genes in our study may be, to a certain extent, a result of smoking prevalence in the CVD group; however, smoking is also an established risk factor of CVD \[[@B2-jcm-09-01251]\] and altered expression of *CDS2*, *TBC1D22A* and *WNK1* could be involved in CVD development through smoking-related mechanisms. Many smoking-induced miRNAs were previously identified and associated with various pathological conditions, including carcinogenesis \[[@B93-jcm-09-01251]\]. Presence of other smoking-related diseases was limited by inclusion patients diagnosed exclusively for CVD, with no other, especially cardiovascular, conditions detected during examination.

PBMCs constitute an important element of inflammation process in vascular diseases \[[@B11-jcm-09-01251]\]; thus, transcriptional profiling of this cell pool should provide reliable information pertinent for vascular pathology. Another advantage of PBMCs is their accessibility through minimally invasive procedures, facilitating utilization in basic and clinical research. Despite of all advantages, co-prevalence of other diseases like chronic obstructive pulmonary disease, hypertension, diabetes mellitus and accompanying complications may bias the evaluation of expression profiles on a systemic scale. To cope with this bias, only subjects without co-existing conditions mentioned in the experimental section were included to the study. Such strict evaluation helped us to find systemic regulatory changes in miRNA and gene expression, which potentially are reflective of local changes in CVD. However, application of these exclusion criteria entailed construction of CVD and control groups with statistically significant differences in age and smoking history, which can introduce some biological bias to our results; therefore, further investigations with more balanced population groups should be performed.

We are aware that our research has several limitations. Studied PBMCs samples may differ in proportions of cell subpopulations (lymphocytes, monocytes), which may introduce a bias in miRNA and gene expression patterns. To assess the impact of this factor, we performed a deconvolution procedure using two methods: "quanTIseq" and "MCPcounter" implemented in an immunedeconv package, enabling comparison between cell types and between samples. The results of deconvolution do not indicate that differences in proportions of particular cell subpopulations across samples which included the CVD and control group had a significant impact on the study outcome ([Figures S8 and S9](#app1-jcm-09-01251){ref-type="app"}).

Due to technical constraints (server capacity), gene expression analysis was performed on the subset of participants subjected to miRNA expression analysis, which may affect the described transcriptomic effect of miRNA expression alterations in CVD patients. Despite this imbalance, we confirmed some previously validated interactions ([Table S11](#app1-jcm-09-01251){ref-type="app"}) and determined with high probability other connections in signaling network ([Table S12](#app1-jcm-09-01251){ref-type="app"}). Future studies should also include in vitro and in vivo validation of predictive interactions of presented miRNA regulatory network. Moreover, in the group selected for gene expression analysis, both miRNA and total RNA were isolated from PBMC specimens obtained from exactly the same subjects and represent the same physiological conditions probed at the same time and circumstances.

Despite applying strict criteria to select the most promising signatures of CVD, the biomarker role of particular miRNAs and gene sets should be confirmed in further studies with larger cohorts and with the application of other validation methods, such as RT-qPCR. Further experiments will involve investigations regarding clinical factors (e.g., stage of disease or medications) and elucidation of whether dysregulations of miRNAs and genes indicative for CVD were predictive of or responsive to the disease development.

The results obtained in our current study confirm the significance of miRNA-dependent epigenetic regulation in the pathogenesis of CVD. Although we proposed a novel biomarker panel of CVD, there is still a need for further research on the role of miRNA regulation in the CVD due to small sample size as well as a clear exploratory and hypothesis-generating character of the presented experiments.

The presented discoveries may be used in further fundamental research and may prove to be useful for clinicians and practitioners, providing new paths in diagnosis, differentiation and treatment procedures for CVD patients in future.

5. Conclusions {#sec5-jcm-09-01251}
==============

Owing to broad and detailed Next Generation Sequencing analysis one is able to draw some general conclusions about CVD. Analysis of microRNAs and genes dysregulated in CVD unveiled numerous terms related to general physiological processes and traits like inflammation, metabolism, aging as well as more specific ones like lipidomics, cardiovascular diseases and chemodependencies. Future research on much numerous groups of patients and controls would broaden our knowledge about cardiovascular diseases, enabling personalized approach to individual patients.

The research was performed using the equipment purchased within the Project "The equipment of innovative laboratories doing research on new medicines used in the therapy of civilization and neoplastic diseases" within the Operational Program Development of Eastern Poland 2007--2013, Priority Axis I Modern Economy, Operations I.3 Innovation Promotion.

The following are available online at <https://www.mdpi.com/2077-0383/9/5/1251/s1>, Figure S1: Distribution of age (A), BMI (B), sex (C) and smoking (D) in CVD and control group. Figure S2: Control plots for miRNA sequencing data. Figure S3: Control plots for transcriptome sequencing data. Figure S4: Plots for UVE-PLS analysis of miRNA expression in CVD group in comparison to control group. Figure S5: Receiver Operating Characteristics (ROC) curves for 34 miRNA transcripts selected as signatures of CVD. Figure S6: Plots for UVE-PLS analysis of genes expression in CVD group compared to control group. Figure S7: Receiver Operating Characteristics (ROC) curves for 62 genes selected as signatures of CVD. Figure S8: Results of gene expression deconvolution procedure for seven CVD patients and seven control subjects performed using "quanTIseq" method implemented to immunedeconv 2.0.0 package. Figure S9: Results of deconvolution procedure performed on gene expression datasets of 7 CVD patients (CVD) and 7 control subjects (Control) using "MCPcounter" method implemented to immunedeconv 2.0.0 package. Table S1: Measurements of small RNA samples and small RNA libraries as well as results of small RNA sequencing data analysis received from Ion Torrent small RNA Plugin v5.0.5r3. Table S2: Measurements of transcriptome libraries and results of transcriptome sequencing data analysis received from Ion Torrent RNASeqAnalysis plugin v.5.0.3.0. Table S3: The set of 96 differentially expressed microRNA transcripts resulted from DESeq2 analysis with *p* \< 0.05 in 34 patients with CVD compared to 19 controls. Table S4: The set of 48 differentially expressed microRNA transcripts resulted from UVE-PLS analysis in in 34 patients with CVD group compared to 19 controls. Table S5: Results of ROC analysis for 34 miRNA transcripts selected as indicative for CVD. Table S6: Correlation analysis between age and expression of 34 selected miRNA transcripts in CVD group. Table S7: 183 differentially expressed genes resulted from DESeq2 analysis with *p* \< 0.00001 in seven patients with CVD, compared to seven controls. Table S8: The set of 74 differentially expressed genes resulted from UVE-PLS analysis in seven patients with CVD compared to seven controls. Table S9: Results of ROC analysis for 62 genes selected as indicative for CVD. Table S10: Correlation analysis between age and expression of 62 selected genes in CVD group. Table S11: Twelve experimentally validated miRNA:gene pairs found among 31 miRNAs and 62 genes indicative for CVD using multiMiR package. Table S12: Top 10%-predicted miRNA:gene pairs found among 31 miRNAs and 62 genes indicative for CVD using multiMiR package.

######

Click here for additional data file.

Conceptualization, A.B.-K., M.F. and J.K.; methodology, A.B.-K., D.P.Z., K.P.R., L.K., M.F. and J.K.; software, D.P.Z., L.K. and J.B.; validation, A.B.-K., D.P.Z., K.P.R. and M.F.; formal analysis, A.B.-K., D.P.Z., K.P.R., P.C. and J.B.; investigation, D.P.Z., K.P.R. and P.K.; resources, A.B.-K., A.S., M.F. and J.K.; data curation, D.P.Z., K.P.R. and A.S.; writing---original draft preparation, D.P.Z. and K.P.R.; writing---review and editing, A.B.-K., D.G. and M.F.; visualization, D.P.Z.; supervision, A.B.-K., A.S., M.F. and J.K.; project administration, A.B-K., A.S. and T.Z.; funding acquisition, A.B-K. and J.K. All authors have read and agreed to the published version of the manuscript.

This research and APC were funded by Statutory Funds of the Medical University of Lublin (number DS43 to A.B.-K.), provided by the Polish Ministry of Science and Higher Education for Medical University of Lublin, Poland.

A.B.-K., D.P.Z., K.P.R., A.S., P.K., T.Z., M.F. and J.K. are co-authors of patent application "Application of microRNA markers for diagnosis of chronic venous disease and method of chronic venous disease diagnosis" No. P.433137, submitted to Polish Patent Office.

All datasets generated for this study can be found in the FigShare repository <https://doi.org/10.6084/m9.figshare.12033738.v1>.

![The scheme of the methodology applied in the study. CVD---chronic venous disease.](jcm-09-01251-g001){#jcm-09-01251-f001}

![Results of differential expression analysis of miRNA in group of 34 patients with chronic venous disease (CVD) vs. 19 healthy controls (Control). (**a**) Venn diagram presenting comparison of two sets of miRNA transcripts: the set of 49 miRNA transcripts resulted from DESeq2 analysis with *p* \< 0.01 and the set of 48 informative miRNA transcripts resulted from Uninformative Variable Elimination by Partial Least Squares (UVE-PLS) analysis. Thirty-four miRNA transcripts were common for both sets. 3D Principal Component Analysis (PCA) plot (**b**) and heatmap with Euclidean clustering (**c**) show differential expression of common 34 miRNA transcripts in CVD and control groups.](jcm-09-01251-g002){#jcm-09-01251-f002}

![Results of differential expression analysis of genes in group of seven patients with chronic venous disease (CVD) vs. seven healthy controls group (Control). (**a**) Venn diagram presenting comparison of two gene sets: the set of 183 genes received from DESeq2 analysis with *p* \< 0.00001 and the set of 74 informative genes indicated by Uninformative Variable Elimination by Partial Least Squares (UVE-PLS) analysis. Sixty-two genes were common for both sets of genes. 3D Principal Component Analysis (PCA) plot (**b**) and heatmap with Euclidean clustering (**c**) show differential expression of common 62 genes in CVD and Control groups.](jcm-09-01251-g003){#jcm-09-01251-f003}

![Regulatory network of interactions found in silico between miRNAs and genes indicated as the most promising biomarkers of chronic venous disease. Upregulated and downregulated nodes (miRNAs or genes) were labeled with red and blue color, respectively. Validated and predictive interactions were labeled with solid and dashed edges, respectively.](jcm-09-01251-g004){#jcm-09-01251-f004}

jcm-09-01251-t001_Table 1

######

Characteristics of 34 patients with chronic venous disease (CVD) and 19 non-CVD controls included in the study.

  Characteristic                                                            CVD Population (*n* = 34)   Control Population (*n* = 19)   *P*
  ------------------------------------------------------------------------- --------------------------- ------------------------------- ----------------
  Age                                                                       44.12 ± 10.07 ^1^           36.58 ± 9.97 ^1^                8.387 × 10^−3^
  27--78 ^2^                                                                24--55 ^2^
  Body Mass Index                                                           23.85 ± 2.35 ^1^            23.12 ± 3.93 ^1^                0.117
  20.13--28.76 ^2^                                                          19.33--32.6 ^2^
  Smoking: Current                                                          5 (14.7%)                   0 (0%)                          1.296 × 10^−4^
  Smoking: Former                                                           13 (38%)                    0 (0%)
  Smoking: Never                                                            16 (47%)                    19 (100%)
  Sex: Male                                                                 17 (50%)                    9 (47%)                         1
  Sex: Female                                                               17 (50%)                    10 (53%)
  **Signs and symptoms**
  Pain                                                                      7 (20.6%)                   NA
  Ankle-brachial index                                                      0.96 ± 0.048 ^1^            NA
  0.71--0.99 ^2^
  **Extended anatomical classification**
  Great saphenous vein (above knee)                                         23 (67.7%)                  NA
  Great saphenous vein (below knee)                                         7 (20.6%)                   NA
  Small saphenous vein                                                      3 (8.8%)                    NA
  Great and small saphenous vein                                            1 (2.9%)                    NA
  **Medication**
  Micronized diosmin                                                        19 (55.9%)                  NA
  Preparation with vitaminum C, hesperidin and *Ruscus aculeatus* extract   10 (29.4%)                  NA
  Both medications                                                          5 (14.7%)                   NA

^1^ mean ± SD, ^2^ range. Statistical significance (*P*) of differences between chronic venous disease (CVD) and control group in age and BMI was calculated using two-sided Mann Whitney *U* test, and in sex and smoking was calculated using Fisher exact test. Inapplicable data were addressed to "NA".

jcm-09-01251-t002_Table 2

######

Set of 34 differentially expressed miRNA transcripts resulted from DESeq2 analysis with *p* \< 0.01 with statistical significance confirmed by UVE-PLS analysis in 34 patients with chronic venous disease compared to 19 controls.

  No.                                   miRNA Transcript                   miRNA ID ^1^        *P*             Fold Change   PLS Coefficient   ROC-AUC
  ------------------------------------- ---------------------------------- ------------------- --------------- ------------- ----------------- ---------
  **Upregulated miRNA Transcripts**
  1\.                                   hsa-mir-122_hsa-miR-122-5p         hsa-miR-122-5p      1.06 × 10^−9^   2.2135        4.71 × 10^−2^     0.930
  2\.                                   hsa-mir-3591_hsa-miR-3591-3p       hsa-miR-3591-3p     1.06 × 10^−9^   2.2127        4.71 × 10^−2^     0.930
  3\.                                   hsa-mir-183_hsa-miR-183-5p         hsa-miR-183-5p      2.05 × 10^−6^   1.9316        3.83 × 10^−2^     0.855
  4\.                                   hsa-mir-1277_hsa-miR-1277-3p       hsa-miR-1277-3p     2.13 × 10^−5^   1.7727        4.04 × 10^−2^     0.850
  5\.                                   hsa-mir-548d-1_hsa-miR-548d-3p     hsa-miR-548d-3p     2.13 × 10^−5^   1.6170        2.09 × 10^−2^     0.859
  6\.                                   hsa-mir-34a_hsa-miR-34a-5p         hsa-miR-34a-5p      3.81 × 10^−5^   1.9308        3.45 × 10^−2^     0.847
  7\.                                   hsa-mir-576_hsa-miR-576-3p         hsa-miR-576-3p      3.04 × 10^−4^   2.0430        3.21 × 10^−2^     0.842
  8\.                                   hsa-mir-454_hsa-miR-454-3p         hsa-miR-454-3p      3.04 × 10^−4^   1.2133        1.05 × 10^−2^     0.833
  9\.                                   hsa-mir-548d-1_hsa-miR-548d-5p     hsa-miR-548d-5p     3.44 × 10^−4^   1.3487        1.47 × 10^−2^     0.836
  10\.                                  hsa-mir-186_hsa-miR-186-3p         hsa-miR-186-3p      3.61 × 10^−4^   1.3568        1.65 × 10^−2^     0.814
  11\.                                  hsa-mir-548d-2_hsa-miR-548d-5p     hsa-miR-548d-5p     3.61 × 10^−4^   1.3498        1.47 × 10^−2^     0.811
  12\.                                  hsa-mir-548aa-1_hsa-miR-548aa      hsa-miR-548aa       5.13 × 10^−4^   1.3248        1.46 × 10^−2^     0.819
  13\.                                  hsa-mir-548aa-2_hsa-miR-548aa      hsa-miR-548aa       1.02 × 10^−3^   1.3381        1.46 × 10^−2^     0.797
  14\.                                  hsa-mir-33a_hsa-miR-33a-5p         hsa-miR-33a-5p      1.02 × 10^−3^   1.2067        1.13 × 10^−2^     0.816
  15\.                                  hsa-mir-590_hsa-miR-590-3p         hsa-miR-590-3p      1.02 × 10^−3^   1.1660        6.74 × 10^−3^     0.816
  16\.                                  hsa-mir-548t_hsa-miR-548t-3p       hsa-miR-548t-3p     1.81 × 10^−3^   1.3233        8.10 × 10^−3^     0.796
  17\.                                  hsa-mir-1277_hsa-miR-1277-5p       hsa-miR-1277-5p     1.84 × 10^−3^   1.3291        2.13 × 10^−2^     0.811
  18\.                                  hsa-let-7b_hsa-let-7b-3p           hsa-let-7b-3p       2.06 × 10^−3^   1.3223        1.09 × 10^−2^     0.791
  19\.                                  hsa-mir-96_hsa-miR-96-5p           hsa-miR-96-5p       3.73 × 10^−3^   2.2914        2.64 × 10^−2^     0.786
  20\.                                  hsa-mir-548ac_hsa-miR-548ac        hsa-miR-548ac       5.53 × 10^−3^   1.7613        2.87 × 10^−2^     0.807
  21\.                                  hsa-mir-19a_hsa-miR-19a-3p         hsa-miR-19a-3p      5.82 × 10^−3^   1.1944        8.38 × 10^−3^     0.757
  22\.                                  hsa-mir-206_hsa-miR-206            hsa-miR-206         8.00 × 10^−3^   2.0356        2.76 × 10^−2^     0.759
  23\.                                  hsa-mir-497_hsa-miR-497-3p         hsa-miR-497-3p      9.31 × 10^−3^   1.4368        1.63 × 10^−2^     0.782
  24\.                                  hsa-mir-208a_hsa-miR-208a-3p       hsa-miR-208a-3p     9.81 × 10^−3^   3.2080        2.77 × 10^−2^     0.789
  **Downregulated miRNA transcripts**
  25\.                                  hsa-mir-92a-1_hsa-miR-92a-3p       hsa-miR-92a-3p      7.89 × 10^−5^   0.8323        −1.40 × 10^−2^    0.856
  26\.                                  hsa-mir-874_hsa-miR-874-5p         hsa-miR-874-5p      1.29 × 10^−4^   0.5428        −3.43 × 10^−2^    0.916
  27\.                                  hsa-mir-106b_hsa-miR-106b-3p       hsa-miR-106b-3p     2.47 × 10^−4^   0.7964        −1.15 × 10^−2^    0.902
  28\.                                  hsa-mir-92a-2_hsa-miR-92a-3p       hsa-miR-92a-3p      3.04 × 10^−4^   0.8414        −1.43 × 10^−2^    0.842
  29\.                                  hsa-mir-181a-2_hsa-miR-181a-2-3p   hsa-miR-181a-2-3p   1.02 × 10^−3^   0.6772        −3.24 × 10^−2^    0.793
  30\.                                  hsa-mir-128-1_hsa-miR-128-3p       hsa-miR-128-3p      2.67 × 10^−3^   0.8504        −7.84 × 10^−3^    0.777
  31\.                                  hsa-mir-769_hsa-miR-769-5p         hsa-miR-769-5p      5.53 × 10^−3^   0.8706        −1.15 × 10^−2^    0.794
  32\.                                  hsa-mir-30e_hsa-miR-30e-3p         hsa-miR-30e-3p      5.53 × 10^−3^   0.7400        −1.51 × 10^−2^    0.805
  33\.                                  hsa-mir-1250_hsa-miR-1250-5p       hsa-miR-1250-5p     8.56 × 10^−3^   0.6186        −3.32 × 10^−2^    0.803
  34\.                                  hsa-mir-25_hsa-miR-25-3p           hsa-miR-25-3p       8.94 × 10^−3^   0.8603        −9.00 × 10^−3^    0.766

^1^ According to miRBase 22 (<http://www.mirbase.org/>). These 34 miRNA transcripts result in 31 miRNAs (miRNA IDs). *P* (FDR with Benjamini--Hochberg correction) and fold change values were obtained from DESeq2 analysis. Partial Least Squares (PLS) coefficients were obtained from Uninformative Variable Elimination by Partial Least Squares (UVE-PLS) analysis. Areas under Receiver Operating Characteristics (ROC) curves (ROC-AUC) were received from ROC analysis. MiRNA transcripts were ordered according to increasing *p* values across groups of upregulated and downregulated miRNA transcripts.

jcm-09-01251-t003_Table 3

######

The set of 62 differentially expressed genes in seven patients with chronic venous disease vs. seven controls, resulted from DESeq2 analysis (*p* \< 0.00001) with statistical significance confirmed by Uninformative Variable Elimination by Partial Least Squares (UVE-PLS) analysis.

  No.                       Gene Symbol            Gene Name                                                                *p* Value        Fold Change   PLS Coefficient    ROC-AUC
  ------------------------- ---------------------- ------------------------------------------------------------------------ ---------------- ------------- ------------------ ---------
  **Upregulated Genes**
  1\.                       *TSC2*                 TSC complex subunit 2                                                    4.87 × 10^−17^   1.437         8.197 × 10^−4^     1.000
  2\.                       *TBC1D22A*             TBC1 domain family member 22A                                            4.36 × 10^−11^   1.431         7.572 × 10^−4^     1.000
  3\.                       *PPP6R2*               protein phosphatase 6 regulatory subunit 2                               9.52 × 10^−9^    1.361         6.225 × 10^−4^     1.000
  4\.                       *UPF1*                 UPF1, RNA helicase and ATPase                                            2.82 × 10^−7^    1.247         5.077 × 10^−4^     1.000
  5\.                       *WNK1*                 WNK lysine deficient protein kinase 1                                    4.59 × 10^−7^    1.258         4.134 × 10^−4^     1.000
  6\.                       *CDS2*                 CDP-diacylglycerol synthase 2                                            5.31 × 10^−7^    1.241         4.756 × 10^−4^     1.000
  7\.                       *PRRC2B*               proline rich coiled-coil 2B                                              1.56 × 10^−6^    1.273         4.693 × 10^−4^     1.000
  8\.                       *HDAC5*                histone deacetylase 5                                                    4.89 × 10^−6^    1.432         5.694 × 10^−4^     1.000
  9\.                       *INTS11* (*CPSF3L*)    integrator complex subunit 11                                            5.95 × 10^−6^    1.246         4.683 × 10^−4^     1.000
  **Downregulated genes**
  10\.                      *AC078899.1*           Unmatched                                                                1.18 × 10^−13^   0.393         −1.586 × 10^−3^    1.000
  11\.                      *RP11-16F15.1*         Unmatched                                                                1.18 × 10^−13^   0.327         −2.068 × 10^−3^    1.000
  12\.                      *EEF1A1P19*            eukaryotic translation elongation factor 1 alpha 1 pseudogene 19         8.40 × 10^−13^   0.500         −1.305 × 10^−3^    1.000
  13\.                      *PFN1P1*               profilin 1 pseudogene 1                                                  4.04 × 10^−11^   0.367         −1.457 × 10^−3^    1.000
  14\.                      *RP4-706A16.3*         Unmatched                                                                4.36 × 10^−11^   0.455         −1.394 × 10^−3^    1.000
  15\.                      *AC005884.1*           Unmatched                                                                4.36 × 10^−11^   0.401         −1.488 × 10^−3^    1.000
  16\.                      *CALM2P2*              calmodulin 2 pseudogene 2                                                4.36 × 10^−11^   0.386         −1.498 × 10^−3^    1.000
  17\.                      *HSPA8P1*              heat shock protein family A (Hsp70) member 8 pseudogene 1                4.36 × 10^−11^   0.379         −1.575 × 10^−3^    1.000
  18\.                      *RP11-490H24.5*        Unmatched                                                                4.36 × 10^−11^   0.312         −1.508 × 10^−3^    1.000
  19\.                      *EIF4A1P10*            eukaryotic translation initiation factor 4A1 pseudogene 10               4.66 × 10^−11^   0.461         −1.286 × 10^−3^    1.000
  20\.                      *RP11-1033A18.1*       Unmatched                                                                7.00 × 10^−11^   0.381         −1.495 × 10^−3^    1.000
  21\.                      *EIF3FP3*              eukaryotic translation initiation factor 3 subunit F pseudogene 3        1.35 × 10^−10^   0.443         −1.423 × 10^−3^    1.000
  22\.                      *PDIA3P1* (*PDIA3P*)   protein disulfide isomerase family A member 3 pseudogene 1               2.38 × 10^−10^   0.465         −1.240 × 10^−3^    1.000
  23\.                      *HSPA9P1*              heat shock protein family A (Hsp70) member 9 pseudogene 1                2.76 × 10^−10^   0.420         −1.414 × 10^−3^    1.000
  24\.                      *AC007238.1*           Unmatched                                                                3.62 × 10^−10^   0.422         −1.398 × 10^−3^    1.000
  25\.                      *HNRNPA1P7*            heterogeneous nuclear ribonucleoprotein A1 pseudogene 7                  3.72 × 10^−10^   0.462         −1.232 × 10^−3^    1.000
  26\.                      *RP11-159C21.4*        Unmatched                                                                4.81 × 10^−10^   0.390         −1.552 × 10^−3^    1.000
  27\.                      *PABPC3*               poly(A) binding protein cytoplasmic 3                                    1.70 × 10^−9^    0.414         −1.468 × 10^−3^    1.000
  28\.                      *RP11-74E24.2*         Unmatched                                                                1.94 × 10^−9^    0.537         −1.067 × 10^−3^    1.000
  29\.                      *EEF1A1P6*             eukaryotic translation elongation factor 1 alpha 1 pseudogene 6          1.94 × 10^−9^    0.441         −1.375 × 10^−3^    1.000
  30\.                      *XRCC6P2*              X-ray repair cross complementing 6 pseudogene 2                          2.89 × 10^−9^    0.373         −1.535 × 10^−3^    1.000
  31\.                      *HNRNPKP2*             heterogeneous nuclear ribonucleoprotein K pseudogene 2                   3.13 × 10^−9^    0.424         −1.163 × 10 \^-3   1.000
  32\.                      *EEF1A1P11*            eukaryotic translation elongation factor 1 alpha 1 pseudogene 11         8.40 × 10^−9^    0.448         −1.369 × 10^−3^    1.000
  33\.                      *UBA52P5*              ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 5   8.40 × 10^−9^    0.397         −1.306 × 10^−3^    1.000
  34\.                      *RPL9P7*               ribosomal protein L9 pseudogene 7                                        9.10 × 10^−9^    0.414         −1.417 × 10^−3^    1.000
  35\.                      *RPS21P4*              ribosomal protein S21 pseudogene 4                                       1.37 × 10^−8^    0.376         −1.531 × 10^−3^    1.000
  36\.                      *RP11-334L9.1*         Unmatched                                                                1.37 × 10^−8^    0.333         −1.206 × 10^−3^    1.000
  37\.                      *HNRNPKP4*             heterogeneous nuclear ribonucleoprotein K pseudogene 4                   1.38 × 10^−8^    0.462         −1.120 × 10^−3^    1.000
  38\.                      *RPL9P9*               ribosomal protein L9 pseudogene 9                                        1.38 × 10^−8^    0.418         −1.302 × 10^−3^    1.000
  39\.                      *AC138123.2*           Unmatched                                                                1.38 × 10^−8^    0.407         −1.422 × 10^−3^    1.000
  40\.                      *HNRNPA1P10*           heterogeneous nuclear ribonucleoprotein A1 pseudogene 10                 1.39 × 10^−8^    0.475         −1.227 × 10^−3^    1.000
  41\.                      *MORF4L1P1*            mortality factor 4 like 1 pseudogene 1                                   3.98 × 10^−8^    0.535         −1.045 × 10^−3^    1.000
  42\.                      *RP11-676M6.1*         Unmatched                                                                8.19 × 10^−8^    0.498         −1.208 × 10^−3^    1.000
  43,                       *RPL7AP66*             ribosomal protein L7a pseudogene 66                                      9.71 × 10^−8^    0.485         −1.089 × 10^−3^    1.000
  44\.                      *RP11-680H20.1*        Unmatched                                                                9.99 × 10^−8^    0.411         −1.155 × 10^−3^    1.000
  45\.                      *CTB-13H5.1*           Unmatched                                                                1.41 × 10^−7^    0.418         −1.175 × 10^−3^    1.000
  46\.                      *HNRNPA1P35*           heterogeneous nuclear ribonucleoprotein A1 pseudogene 35                 1.49 × 10^−7^    0.350         −1.223 × 10^−3^    1.000
  47\.                      *PTBP1P*               polypyrimidine tract binding protein 1 pseudogene                        1.53 × 10^−7^    0.443         −1.095 × 10^−3^    1.000
  48\.                      *API5P1*               apoptosis inhibitor 5 pseudogene 1                                       1.57 × 10^−7^    0.347         −1.204 × 10^−3^    1.000
  49\.                      *UBE2D3P1*             ubiquitin conjugating enzyme E2 D3 pseudogene 1                          1.69 × 10^−7^    0.485         −8.801 × 10^−4^    1.000
  50\.                      *AL162151.3*           Unmatched                                                                1.94 × 10^−7^    0.431         −1.258 × 10^−3^    1.000
  51\.                      *RPL9P8*               ribosomal protein L9 pseudogene 8                                        2.34 × 10^−7^    0.446         −1.253 × 10^−3^    1.000
  52\.                      *EEF1A1P13*            eukaryotic translation elongation factor 1 alpha 1 pseudogene 13         2.51 × 10^−7^    0.521         −1.211 × 10^−3^    1.000
  53\.                      *PABPC1P4*             poly(A) binding protein cytoplasmic 1 pseudogene 4                       2.60 × 10^−7^    0.465         −1.031 × 10^−3^    1.000
  54\.                      *HNRNPUP1*             heterogeneous nuclear ribonucleoprotein U pseudogene 1                   2.73 × 10^−7^    0.441         −1.106 × 10^−3^    1.000
  55\.                      *ARPC3P1*              actin related protein 2/3 complex subunit 3 pseudogene 1                 3.72 × 10^−7^    0.331         −1.272 × 10^−3^    1.000
  56\.                      *PTP4A2P1*             protein tyrosine phosphatase type IVA, member 2 pseudogene 1             4.59 × 10^−7^    0.500         −9.014 × 10^−4^    1.000
  57\.                      *CTC-451P13.1*         Unmatched                                                                4.77 × 10^−7^    0.513         −9.263 × 10^−4^    1.000
  58\.                      *BZW1P2*               basic leucine zipper and W2 domains 1 pseudogene 2                       7.97 × 10^−7^    0.445         −9.598 × 10^−4^    1.000
  59\.                      *RP11-318C24.1*        Unmatched                                                                1.94 × 10^−6^    0.314         −1.062 × 10^−3^    0.980
  60\.                      *OTUD4P1* (*HIN1L*)    OTUD4 pseudogene 1                                                       2.08 × 10^−6^    0.480         −9.962 × 10^−4^    1.000
  61\.                      *EIF3LP2*              eukaryotic translation initiation factor 3 subunit L pseudogene 2        2.33 × 10^−6^    0.457         −9.995 × 10^−4^    1.000
  62\.                      *RAC1P2*               Rac family small GTPase 1 pseudogene 2                                   3.29 × 10^−6^    0.489         −8.192 × 10^−4^    0.980

*P* (FDR with Benjamini--Hochberg correction) and fold change values were obtained from DESeq2 analysis. PLS coefficients were obtained from UVE-PLS analysis. Areas under Receiver Operating Characteristics (ROC) curves (ROC-AUC) were received from ROC analysis. Genes were ordered according to increasing *p* values across groups of upregulated and downregulated genes. Genes without names assigned by HUGO Multi-symbol checker were termed as "Unmatched". Synonyms or previous gene symbols were put into brackets.

jcm-09-01251-t004_Table 4

######

Results of functional analysis of seven genes selected in silico as targets of miRNA identified as signatures of chronic venous disease.

  Functional Analysis of Upregulated Genes (*CDS2, HDAC5, PPP6R2, PRRC2B, TBC1D22A, WNK1*)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *KEGG, Reactome, GAD and GAD Class*
  *CDS2*                                                                                KEGG: Glycerophospholipid metabolism, Phosphatidylinositol signaling system, Metabolic pathways
  Reactome: Synthesis of PG (Phosphatidylglycerol)
  GAD: Type 2 Diabetes\|edema\|rosiglitazone, Tobacco Use Disorder
  GAD Class: pharmacogenomic, chemdependency
  *HDAC5*                                                                                KEGG: Alcoholism, Viral carcinogenesis,
  Reactome: NOTCH1 Intracellular Domain Regulates Transcription, Constitutive Signaling by NOTCH1 PEST Domain Mutants, Constitutive Signaling by NOTCH1 HD + PEST Domain Mutants
  GAD: antidepressant response, Bone Density, Bone mineral density (hip), Bone mineral density (spine), bronchodilator response, Fractures, Bone, Type 2 Diabetes\| edema \| rosiglitazone
  GAD Class: immune, metabolic, pharmacogenomic
  *PPP6R2*                                                                                No information
  *PRRC2B*                                                                                No information
  *TBC1D22A*                                                                                GAD: Albumins, Arteries, Attention Deficit Disorder with Hyperactivity, Blood Pressure, Body Mass Index, Body Weight, Breath Tests, Cardiomegaly, Cholesterol, Erythrocyte Count, Fibrinogen, Heart Failure, Heart Rate, Leukocyte Count, longevity, Metabolism, Myocardial Infarction, Parkinson Disease, Resistin, Stroke, Thyrotropin, Tobacco Use Disorder, Waist Circumference, Waist-Hip Ratio
  GAD Class: aging, cardiovascular, chemdependency, hematological, immune, metabolic, neurological, other, psych
  *WNK1*                                                                                Reactome: Stimuli-sensing channels
  GAD: Apoplexy\|Brain Ischemia\|Stroke, blood pressure, arterial, Chronic renal failure\|Kidney Failure, Chronic, Essential Hypertension, Hereditary Sensory and Autonomic Neuropathies, HIV Infections\|\[X\]Human immunodeficiency virus disease, hypertension, null, Tobacco Use Disorder, Type 2 Diabetes\| edema \| rosiglitazone
  GAD Class: cardiovascular, chemdependency, infection, neurological, pharmacogenomic, renal, unknown
  *Gene Ontology terms associated with EASE score \<0.1*
  GO Biological Process                                                                                cellular developmental process, positive regulation of molecular function
  GO Molecular Function                                                                                enzyme binding
  Functional analysis of downregulated gene (*PABPC3*)
  *KEGG, Reactome, GAD and GAD Class*
  *PABPC3*                                                                                KEGG: RNA transport, mRNA surveillance pathway, RNA degradation
  GAD: Body Mass Index, Body Weight, Body Weight Changes, Glomerular Filtration Rate
  GAD Class: metabolic, renal
  *Gene Ontology terms associated with PABPC3*
  GO Biological Process                                                                                nucleobase-containing compound metabolic process, cellular aromatic compound metabolic process, nitrogen compound metabolic process, metabolic process, cellular process, RNA metabolic process, mRNA metabolic process, cellular nitrogen compound metabolic process, macromolecule metabolic process, cellular metabolic process, primary metabolic process, cellular macromolecule metabolic process, heterocycle metabolic process, organic substance metabolic process, nucleic acid metabolic process, organic cyclic compound metabolic process
  GO Molecular Function                                                                                nucleotide binding, nucleic acid binding, RNA binding, single-stranded RNA binding, binding, poly(A) binding, small molecule binding, poly-purine tract binding, organic cyclic compound binding, nucleoside phosphate binding, heterocyclic compound binding
  GO Cellular Component                                                                                extracellular region, intracellular, cell, cytoplasm, vesicle, membrane-bounded vesicle, organelle, membrane-bounded organelle, extracellular organelle, extracellular region part, intracellular part, cell part, extracellular exosome, extracellular vesicle

Analysis was carried out with DAVID 6.8 website tool and all associated functional terms of Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, Genetic Association Database (GAD), Genetic Association Database Class (GAD Class) categories are presented. Gene Ontology (GO) terms associated with upregulated genes with EASE score (*p*) \< 0.1 are presented. For downregulated gene, all associated GO terms were presented.

[^1]: D.P.Z. and K.P.R. shared first authorship.

[^2]: M.F., J.K. and A.B.-K shared senior authorship.


<?php

/*
 * This file is part of Twig.
 *
 * (c) Fabien Potencier
 *
 * For the full copyright and license information, please view the LICENSE
 * file that was distributed with this source code.
 */

class Twig_Tests_Node_Expression_Unary_NotTest extends Twig_Test_NodeTestCase
{
    public function testConstructor()
    {
        $expr = new Twig_Node_Expression_Constant(1, 1);
        $node = new Twig_Node_Expression_Unary_Not($expr, 1);

        $this->assertEquals($expr, $node->getNode('node'));
    }

    public function getTests()
    {
        $node = new Twig_Node_Expression_Constant(1, 1);
        $node = new Twig_Node_Expression_Unary_Not($node, 1);

        return array(
            array($node, '!1'),
        );
    }
}


<!doctype html>

	<meta charset="UTF-8" />
	<title>QUnit SubsuiteRunner Test Suite</title>

	<link rel="stylesheet" href="../../qunit/qunit.css" type="text/css" media="screen">
	<link rel="stylesheet" href="qunit-composite.css">


netcdf test_struct_array {
types:
  compound s_t {
    int x ;
    int y ;
  }; // s_t
dimensions:
	dx = 4 ;
	dy = 3 ;
variables:
	s_t s(dx, dy) ;

data:

 s =
  {1, -1}, {17, 37}, {-32767, 32767},
  {-1, 3}, {-2, 2}, {-3, 1},
  {-4, 12}, {-8, 8}, {-12, 4},
  {-5, 15}, {-10, 10}, {-15, 5} ;
}


Description: The Journal of Law, Economics & Organization is an interdisciplinary exercise. It seeks to promote an understanding of many complex phenomena by examining such matters from a combined law, economics, and organization perspective (or a two-way combination thereof). In this connection, we use the term organization broadly - to include scholarship drawing on political science, psychology and sociology, among other fields. It also holds the study of institutions - especially economic, legal, and political institutions - to be specifically important and greatly in need of careful analytic study.

The "moving wall" represents the time period between the last issue
available in JSTOR and the most recently published issue of a journal.
Moving walls are generally represented in years. In rare instances, a
publisher has elected to have a "zero" moving wall, so their current
issues are available in JSTOR shortly after publication.
Note: In calculating the moving wall, the current year is not counted.
For example, if the current year is 2008 and a journal has a 5 year
moving wall, articles from the year 2002 are available.

Terms Related to the Moving Wall

Fixed walls: Journals with no new volumes being added to the archive.

Absorbed: Journals that are combined with another title.

Complete: Journals that are no longer published or that have been
combined with another title.

Abstract

In the past 15 years a scholarly debate has developed in the United States over the question "Who controls the bureaucracy?" Some have argued that Congress has a dominant influence on the bureaucracy, some that the president plays the major role in managing the bureaucracy, and others have emphasized the role of legal constraints on the bureaucracy, as enforced by the courts. Still others have asserted that the bureaucracy has a substantial amount of autonomy from the president, Congress, and courts. This article presents a formal model of multi-institutional policy-making that illuminates several key aspects of this debate. The model shows that there are conditions under which an agency will have considerable autonomy and conditions under which it will have virtually none. The model also shows that when an agency lacks autonomy, control of the agency usually cannot be attributed to just one institution. Finally, the model has some important implications for empirical tests of hypotheses about who controls the bureaucracy; among them is the fact that the empirical literature on control of the bureaucracy is based on a logic that gives a seriously incomplete picture of how the bureaucracy is controlled and who controls it.


I took mine apart to peek inside when it was shot from being filled with water. The little diagram that breaks and allows water in is on the inside of the circuit board. The board is placed on plastic pegs, then the plastic is melted to secure it. You'd have to break it out. If water got in there, it's likely done.


494 So.2d 505 (1986)
Isaac HAMILTON, Appellant,
v.
STATE of Florida, Appellee.
No. 84-2642.
District Court of Appeal of Florida, Second District.
August 13, 1986.
Rehearing Denied September 16, 1986.
James Marion Moorman, Public Defender, and A.N. Radabaugh, Asst. Public Defender, Bartow, for appellant.
Jim Smith, Atty. Gen., Tallahassee, and Katherine V. Blanco, Asst. Atty. Gen., Tampa, for appellee.
DANAHY, Chief Judge.
The defendant appeals his conviction for first degree felony robbery. We reject the defendant's assertions of error in connection with his trial, but we agree with the defendant that under the facts of this case he could be convicted only of a second degree felony.
The defendant was charged with robbing a bank in Pasco County. The information alleged that during the course of the robbery the defendant threatened to use a firearm. No firearm was discovered in connection with the case, and none was tendered as evidence at trial. Neither the bank teller nor her supervisor, the only two people in the bank at the time of the robbery, actually saw a weapon during the course of the robbery. The teller testified that the robber told her to hurry up or he would blow her head off. The supervisor thought the robber had a gun because of the way the robber patted his stomach.
The state concedes that the information against the defendant did not charge armed robbery and that the evidence at trial did not establish an armed robbery. Instead, the state takes the position that it intended to charge the defendant with a simple robbery under section 812.13, Florida Statutes (1985), and use the allegation of threat to use a firearm as grounds for enhancement of the robbery from a second degree felony to a first degree felony under the provisions of section 775.087(1)(b), Florida Statutes (1985). The trial judge agreed with the state's enhancement argument and entered a judgment finding the defendant guilty of a first degree felony robbery.
Section 775.087(1) provides for enhancement of the degree of a felony if during the commission of the felony the defendant *506 "threatens to use any weapon or firearm." However, that statute begins with the phrase, "unless otherwise provided by law." Section 812.13(2)(c) specifically provides that "if in the course of committing the robbery the offender carried no firearm, deadly weapon, or other weapon, then the robbery is a felony of the second degree."
Accordingly, we find that the enhancement statute, section 775.087, does not apply in this case because of the express provision of section 812.13(2)(c). We reverse the defendant's conviction with directions that a judgment be entered finding him guilty of a second degree felony robbery and that he be resentenced accordingly.
Reversed and remanded.
RYDER and FRANK, JJ., concur.


How I Came to Love the Klosterman: True Story *

The truth is, I first hated Chuck Klosterman. The reason for this is simple: The first piece of his that I read was the Lloyd Dobbler essay that starts Sex, Drugs, and Coca Puffs. The premise is that every woman of a certain age wants Lloyd Dobbler, the sensitive, kickboxing, eminently quotable character played by John Cusack in Say Anything. Lloyd has awesome female friends (including Lili Taylor, whose "Joe Lies" is another of those eminently quotable pre-Vanilla Sky Cameron Crowe creations); guides his love interest, Diane Court (Ione Skye), around broken glass in a mini-market parking lot (spurring an MxPx lyric that goes, "Do you care when I tell you / step around that broken glass?" sung with all the earnestness a Christian pop-punk band from Bremerton can muster, which is considerable); doesn't want to be part of the machine; and, most famously, stands outside Diane's window holding a boom box above his head as Peter Gabriel's "In Your Eyes" plays (and thereby rendering many of us women of a certain age embarrassingly susceptible to this song).

The problem with this essay? My entire response was a big DUH. Duh, Chuck. Everyone knows this. This is so obvious it doesn't merit saying. It embarrasses me to have to read it put into words â€”Â by a dude, no less!

I put down the book and didn't pick it back up again. But I read a few Klosterman columns in Spin, and I observed from the sidelines as what seemed like an entire generation of geeks and would-be geeks went cuckoo for Klosterman puffs. I watched, I read a little, I forgot about it. I noticed he had new books. A very trusted friend had told me, ages before, that my secret-metal-past self really ought to read Fargo Rock City, and I still wanted to. Kind of.

But I didn't.

And then, one evening, I mixed up the start time of my writing group with the start time of my nerdy book group and found myself at a friend's house half an hour early. I sat on her leopard print lounge-sofa thing and picked up Killing Yourself to Live from the side table to entertain myself with, thereby staying out of her way.

And that was that. I saw it, all of a sudden: the combination of self-centered semi-charm, wit, cleverness and a willingness to insert himself into things that everyone already knows, thereby making them a little different, that makes Klosterman work. Maybe that doesn't make any sense. But imagine a story that you know that's kind of interesting. Maybe it's about a dead rock star. Isn't it fun to imagine that the story would be even more interesting if you wrote yourself into it, somehow? If you and your relationship problems, alone in a car on a road trip, could perhaps add to the famous story? No, that's not a good explanation either. But Klosterman is Klosterman (TM) because he writes himself into things everyone already knows, and he somehow, mysteriously, makes them more interesting that way. I think.

This is also, of course, why some people don't like Klosterman: They're not interested in him, and you pretty much have to be interested in him to be interested in the way he writes about things.

Eventually I had to put down Killing Yourself to Live and pay attention to my writing group, who had some very helpful things to say about a "story" (in quotes to indicate the fact that it was a very thinly disguised slice of the summer of 2000) that I've not touched since. But I have, since then, read all the Klosterman I could get my hands on. Even Cocoa Puffs. In some places, it was great that I hadn't read him before; for instance, I wouldn't have been able to properly appreciate the story about Phoenix Suns point guard Steve Nash if I hadn't, the year before, very quickly learned to appreciate Steve Nash.

But there's one real reason I fell for the image of Chuck Klosterman he presents in his books, and began to get that weird, sort of ooky feeling like, "I totally get this guy! We should be friends!" True story: I fell for the Klosterman thing because of one sentence. One I should have written down, but in essence, it said that the last few minutes of Guns N' Roses "Rocket Queen" are some of the best rock music minutes ever. Not in those words, but that, if I'm not mistaken, was the sentiment.

This is true. This, to a fan of anything that falls under the rock music umbrella, should be undeniable. You have to wade through the (fake, one hopes) orgasm sounds to get to this part of the song, but then, all of a sudden, like a downpour ending when you step outside, the good part arrives. The pretty part. The sensitive part. The part so sweet it puts "Sweet Child O' Mine" to shame.

And why am I writing about this now? Because over at Esquire.com, Klosterman has a very entertaining column up that examines the kind of music he likes, and whether it says anything about him. It's perceptive and funny, and my favorite line is this: "it appears my dream musical creation would be a white, semigay metal band that features soaring background vocals while battling anorexia." You'l have to read the piece for this to make sense. But you'll also have to listen: Klosterman has thoughtfully provided little clips of the bits of music that he likes best.

I listened to a lot of them, but not all. I'm definitely with him on "Nightswimming" and "Since U Been Gone" and obviously "Rocket Queen," but I strongly dislike both "Dance the Night Away" (especially the backing vocals) and "Layla." But what else would I add to this list? Off the top of my head, without clips:

â€¢ The end of Nine Inch Nails' "Hurt," where it builds and builds and builds until destroying itself.

â€¢ The beginning of Superchunk's cover of Magnetic Fields' "100,000 Fireflies," as Mac yelps "I have a mandolin / I play it all night long / It makes me want to kill myself!"

â€¢ Pretty much everything on the Rushmore soundtrack

â€¢ The palm-muted (I think) guitar bits in Jawbreaker's "Chesterfield King," as Blake Schwarzenbach sings "Gave her a dime / and a Chesterfield / She bent down to kiss my cheek / I was scared but it felt sweet." Or really pretty much anytime in a Jawbreaker song where there's a choppy, muted guitar part and Blake's sort of chanting. There should be more Jawbreaker knockoff bands.

â€¢ Jon Auer and Ken Stringfellow harmonizing. Period.

â€¢ Teenage Fanclub's "Is This Music?" In high school, I thought it was bizarro bagpipes. I'm still not exactly sure what it is.

â€¢ OK, I'm going to come back to this, because I'm at work without my CD collection and I want to make this list longer and better and more thorough. Also, to be honest, it needs to have some hair metal in it for sure. But no power ballads!

* You must read this post-colon part of the title as if it's being yelped by cowboy-hat-wearing Jon on the second season of The Real World. It goes something like this: "Tar-ooo stah-oray!"


# Copyright 2013-2020 Lawrence Livermore National Security, LLC and other
# Spack Project Developers. See the top-level COPYRIGHT file for details.
#
# SPDX-License-Identifier: (Apache-2.0 OR MIT)

from spack import *

class PerlRegexpCommon(PerlPackage):
    """Regexp::Common - Provide commonly requested regular expressions"""

    homepage = "https://metacpan.org/pod/Regexp::Common"
    url      = "https://cpan.metacpan.org/authors/id/A/AB/ABIGAIL/Regexp-Common-2017060201.tar.gz"

    version('2017060201', sha256='ee07853aee06f310e040b6bf1a0199a18d81896d3219b9b35c9630d0eb69089b')


Rohtang tunnel: Sonia lays foundation stone

Manali: UPA Chairperson Sonia Gandhi today kicked off the drilling work of 8.8 km Rohtang Tunnel at Dhundi near Manali in Himachal. Terming it a “happy and historic” occasion for the nation she asked the Border Roads Organisation (BRO) to ensure that there was no ecological degradation during the drilling.

Addressing a public meeting at Solang valley, Ms Gandhi said it was a dream project of former prime minister Rajiv Gandhi.

She also expressed the hope that the BRO would complete the 8.8-km tunnel work within the deadline of 2015, when it would be thrown open for the public to drive through from Manali to Keylong without having to touch the icy heights of Rohtang Pass at an altitude of 3,978 metres.

Recalling that former Prime Minister Atal Bihari Vajpayee had laid the foundation stone for the approach roads to the tunnel in 2002, Gandhi said the tunnel, conceived during the Prime Ministership of Indira Gandhi in 1983 and later approved in 1987 during Rajiv Gandhi’s regime, would help connect the tribal areas of Lahaul-Spiti in the state with other parts of the country all year long.

“The tunnel will also provide for an alternative, all-weather road route for the civilians and armed forces to strategically important Ladakh region in Jammu and Kashmir,” she said, acknowledging that the construction at this altitude of over 3,000 metres was a “difficult and challenging” job.

She said HP Chief Minister Prem Kumar Dhumal had placed certain demands for development projects, as did her party colleagues from the state. Among them were proposals for a special hospital for the region and an airport, which she promised to take up with Central Ministers.

Mr. Dhumal in his address said the Rohtang tunnel would meet the long-standing demand of the region for yearlong connectivity and help the armed forces who had to carry out air maintenance of troops deployed in Ladakh in the winters.

Pointing to the infrastructure development done by China along its borders with India, Dhumal made a demand for a railway line via the region to Leh that would help in transporting heavy equipment including battle tanks for the armed forces, apart from enabling passenger traffic.

Mr. Dhumal made a plea with Defence Minister A. K. Antony to review and change the Recruitable Male Population formula for enlisting armed forces personnel and allow all willing youth from the state to become soldiers.

Defence Minister Mr. Antony, in his address said the tunnel construction would be completed within 63 months to be ready by 2015 and the Defence Ministry had set up a steering committee under an Additional Secretary to monitor the work and remove impediments immediately.

Drilling work also started at the exit point, joining the Manali-Sarchu road, over Chandra river. The tunnel will incorporate semi-transverse ventilation system, where large fans would separately circulate air, in and out throughout the tunnel length and thus reduce vehicular fumes.

Strabag-Afcons, a joint venture between India’s Afcons Infrastructure Ltd and Strabag SE of Austria will construct the tunnel under the aegis of BRO.


//===----------------------------------------------------------------------===//
//
// Part of the LLVM Project, under the Apache License v2.0 with LLVM Exceptions.
// See https://llvm.org/LICENSE.txt for license information.
// SPDX-License-Identifier: Apache-2.0 WITH LLVM-exception
//
//===----------------------------------------------------------------------===//

// <cctype>

#include <cctype>

#ifndef _LIBCPP_VERSION
#error _LIBCPP_VERSION not defined
#endif

int main(int, char**)
{

  return 0;
}


Higher operating temperatures for gas turbine engines are continuously sought in order to increase their efficiency. However, as operating temperatures increase, the high temperature durability of the components of the engine must correspondingly increase. Significant advances in high temperature capabilities have been achieved through the formulation of nickel and cobalt-base superalloys. Nonetheless, when used to form components of the turbine, combustor and augmentor sections of a gas turbine engine, such alloys alone are often susceptible to damage by oxidation and hot corrosion attack and may not retain adequate mechanical properties. For this reason, these components are often protected by an environmental and/or thermal-insulating coating, the latter of which is termed a thermal barrier coating (TBC) system. Ceramic materials, and particularly yttria-stabilized zirconia (YSZ), are widely used as a thermal barrier coating (TBC), or topcoat, of TBC systems used on gas turbine engine components. These particular materials are widely employed because they can be readily deposited by plasma spray, flame spray and vapor deposition techniques. A commonly used type of TBC is a coating based on zirconia stabilized with yttria, for example about 93 wt. % zirconia stabilized with about 7 wt. % yttria. This general type of TBC has been reported in such United States patents as U.S. Pat. No. 4,055,705, U.S. Pat. No. 4,328,285, and U.S. Pat. No. 5,236,745, which are incorporated herein by reference.
During routine operation of the engine and aircraft, the coated surfaces, particularly those in or near the flowpath (intake, compression, combustion and exhaust) of the gas turbine engine, are subjected to heat, pressure and other forces can cause the coating to suffer localized damage such as spallation due to thermal fatigue and stress, defects, impact damage and other mechanical damage. For these reasons, the coated surfaces must be routinely inspected and meticulously repaired to avoid further damage to the coated surfaces and the underlying substrate. Maintenance personnel must inspect all visible surfaces, often requiring the use of flashlights, mirrors, and other inspection tools to access remote areas such as the small cooling holes and exhaust ports in a gas turbine engine. In the case of aircraft turbine engines and large power generation turbines, removing the turbine from service for repairs results in significant costs in terms of labor and downtime. For these reasons, removing components having TBCs that have suffered only localized damage such as spallation is not economically desirable. As a result, components identified as having only localized coating damage are often analyzed to determine whether the damage has occurred in a high stress area, and a judgment is then made as to the risk of damage to the turbine due to the reduced thermal protection of the component that could lead to catastrophic failure of the component.
Once a localized damaged coating area is located by inspection, and the decision is made to effect a field repair in situ, maintenance personnel must clean and prime the damaged area. Optionally, the field personnel may also apply a repair coating composition to the damaged surface, such as the compositions described in commonly-owned U.S. Pat. No. 6,413,578, for example. Current tools for cleaning, priming and optionally applying a repair coating are inadequate. Known tools are often too large, too small, or otherwise insufficient to perform the cleaning, priming and repairs. For example, maintenance personnel often use spray bottles and other containers for dispensing cleaning solutions such as solvents and detergents, beakers containing primers and coating repair compositions, and multiple brushes for cleaning and applying cleaning solutions, primers and repair compositions. In addition to the cumbersome use of so many different items, this situation creates a safety hazard to the personnel as well as a mechanical hazard to subsequent operation of the engine. While maintenance protocols require an accounting of each item used in the engine area, the use of a large number of tools makes the accounting process difficult, and more prone to errors that can have catastrophic results.
For all these reasons, there exists a continuing need for maintenance tools that can be effectively and efficiently used in limited access areas of engine and flowpath areas to clean, prime, and optionally repair damaged coated surfaces. There is additionally a need for maintenance tools and cleaning methods that can be used to perform one or more of the tasks of cleaning, priming, and repairing of coated surfaces in situ.
Accordingly, it would be desirable if a cleaning, priming and repair method were available that could be performed on localized damaged areas of TBC on turbine hardware in field and in situ, without necessitating that the component be removed from the turbine, so that downtime and scrappage are minimized.